Alignment Healthcare, Inc. Common Stock
ALHC
$20.50
-4.12%
Alignment Healthcare, Inc. is a technology-driven healthcare company that provides Medicare Advantage plans directly to seniors, operating within the Medical - Healthcare Plans industry. The company positions itself as a next-generation, consumer-centric platform, distinguishing itself through a direct-to-consumer sales model and a proprietary clinical model aimed at improving health outcomes. The current investor narrative is heavily influenced by regulatory developments in Medicare Advantage funding, with recent news of a larger-than-expected 2027 payment increase from the Centers for Medicare & Medicaid Services (CMS) boosting sector-wide sentiment and revenue visibility for players like Alignment.…
ALHC
Alignment Healthcare, Inc. Common Stock
$20.50
Investment Opinion: Should I buy ALHC Today?
Rating: Hold. The core thesis is that ALHC presents a high-risk, high-potential-reward situation where compelling revenue growth and a cheap sales multiple are counterbalanced by severe profitability issues and leverage, making it unsuitable for most investors until the path to profits clarifies.
Supporting this Hold rating are several specific data points: the stock trades at a low Price-to-Sales of 0.99, revenue is growing at a robust 44.4% YoY, and TTM free cash flow is strong at $123.7M. However, these positives are offset by a negative ROE of -0.40%, a high debt-to-equity of 1.89, and a forward P/E of 29.1 (based on estimated EPS) which is expensive for a company not yet reliably profitable. The lack of an analyst price target further muddies the valuation picture.
The thesis would upgrade to a Buy if the company demonstrates two consecutive quarters of expanding gross margins above 12% and positive net income, confirming a turnaround. It would downgrade to a Sell if revenue growth decelerates below 25% YoY or if the debt-to-equity ratio climbs above 2.5, signaling escalating financial stress. Based on the current data, the stock is fairly valued relative to its own troubled history but remains overvalued on an earnings basis, trading on hope of future profitability rather than present results.
Sign up to view all
ALHC 12-Month Price Forecast
ALHC is a binary story where the attractive valuation on sales and powerful growth are entirely contingent on achieving profitability, which the recent margin compression and Q4 loss call into question. The neutral stance reflects this standoff; the stock is not a buy until margins stabilize and turn upward, but the deeply depressed sales multiple provides a floor if the business model is ultimately viable. Confidence is medium because the key variable—medical cost management—is largely outside investor visibility. The stance would upgrade to bullish on confirmation of sustained margin expansion and downgrade to bearish on another quarter of significant margin deterioration or a growth slowdown below 30%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Alignment Healthcare, Inc. Common Stock's 12-month outlook, with a consensus price target around $26.65 and implied upside of +30.0% versus the current price.
Average Target
$26.65
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$16 - $27
Analyst target range
Analyst coverage for ALHC is limited, with only 3 analysts providing estimates, indicating this is a smaller-cap stock with less institutional research focus which can contribute to higher volatility. The available data provides consensus estimates for EPS and revenue but does not include a consensus price target, buy/hold/sell distribution, or a target price range. Therefore, it is impossible to calculate implied upside/downside or gauge the bullish/bearish leaning of analyst sentiment. The lack of a published target range means there is no clear signal on the assumptions behind high and low price scenarios. The pattern from recent institutional ratings shows stability, with firms like JP Morgan, TD Cowen, and Piper Sandler maintaining 'Overweight' or 'Buy' ratings, and UBS maintaining 'Neutral', with no downgrades in the provided recent history. This limited but generally positive rating stability, in the absence of price targets, suggests analysts are cautiously optimistic on the business model but require more data to set firm valuation expectations.
Bulls vs Bears: ALHC Investment Factors
The bull case for ALHC is anchored in its powerful 44%+ revenue growth, a favorable regulatory shift, and a historically low sales multiple that could offer significant upside if profitability emerges. The bear case is equally compelling, focusing on the company's erratic and recently negative profitability, deteriorating gross margins, and high financial leverage. Currently, the bearish evidence holds stronger weight because profitability is the fundamental linchpin for any growth story, and ALHC has failed to demonstrate it consistently. The single most important tension in the investment debate is whether the company's robust top-line growth can translate into sustainable and expanding margins before its leveraged balance sheet or investor patience runs out. The resolution of this profitability question will definitively determine if the stock is a deep-value turnaround or a value trap.
Bullish
- Strong Revenue Growth Trajectory: Q4 2025 revenue grew 44.4% year-over-year to $1.01 billion, demonstrating robust demand for its Medicare Advantage plans. This growth is a significant improvement from the losses reported in 2024, indicating successful market penetration and scaling.
- Positive Regulatory Catalyst: Recent news of a larger-than-expected 2027 Medicare Advantage payment increase from CMS boosts sector-wide revenue visibility. This directly benefits ALHC's core business model, providing a tailwind for future premium growth and reducing regulatory uncertainty.
- Attractive Sales-Based Valuation: The stock trades at a trailing Price-to-Sales (PS) ratio of 0.99, near the bottom of its multi-year historical range which has seen peaks above 13. This suggests the market has priced in significant skepticism, offering a potential value opportunity if execution improves.
- Strong Free Cash Flow Generation: Trailing-twelve-month free cash flow is a robust $123.7 million. This provides the company with internal funding capacity for growth and operational flexibility, reducing near-term liquidity risk despite its net losses.
Bearish
- Inconsistent and Negative Profitability: The company swung to a Q4 2025 net loss of -$11.0 million after two profitable quarters, with a trailing net margin of -0.02%. This volatility and lack of a sustained path to GAAP profitability raises serious questions about the underlying unit economics and cost control.
- Significant Margin Compression: Q4 2025 gross margin compressed to 10.47%, down from 12.65% in Q3 2025 and 13.15% in Q2 2025. This sequential decline indicates rising medical costs or pricing pressure, directly threatening the scalability of its revenue growth.
- High Financial Leverage: The debt-to-equity ratio is elevated at 1.89, signaling a leveraged capital structure. This increases financial risk and interest expense burden, which is problematic for a company with inconsistent earnings, as seen with the $3.95M interest expense in Q4.
- Extreme Stock Volatility and Weakness: The stock has a beta of 1.201 and has significantly underperformed the S&P 500 over one year (+3.64% vs. +29.52%). Its 52-week range of $11.625 to $23.87 highlights high volatility, and its current price is 14% below the high, showing a lack of sustained momentum.
ALHC Technical Analysis
The stock is in a volatile, range-bound consolidation phase with a slight positive bias over the longer term. The 1-year price change of 3.64% significantly underperformed the S&P 500's 29.52% gain, indicating relative weakness. The current price of $20.50 sits approximately 60% above its 52-week low of $11.625 and 14% below its 52-week high of $23.87, placing it in the middle-to-upper portion of its annual range, suggesting it has recovered from lows but lacks the momentum to challenge recent highs. Recent momentum shows a sharp divergence, with a strong 1-month gain of 13.83% contrasting with a 3-month decline of -1.35%, indicating a powerful short-term rally that has reversed the prior quarter's weakness, likely fueled by positive sector news. The stock's beta of 1.201 indicates it is approximately 20% more volatile than the broader market, which is relevant for risk assessment. Key technical levels are clearly defined by the 52-week high of $23.87 as major resistance and the 52-week low of $11.625 as significant support; a decisive breakout above $23.87 would signal a resumption of the prior uptrend, while a breakdown below $16.62 (the recent March low) could indicate a retest of lower support levels.
Beta
1.20
1.20x market volatility
Max Drawdown
-41.1%
Largest decline past year
52-Week Range
$12-$24
Price range past year
Annual Return
+3.6%
Cumulative gain past year
| Period | ALHC Return | S&P 500 |
|---|---|---|
| 1m | +13.8% | +2.6% |
| 3m | -1.3% | -2.3% |
| 6m | +18.4% | +2.6% |
| 1y | +3.6% | +27.3% |
| ytd | +1.4% | -0.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALHC Fundamental Analysis
Revenue growth is robust but shows signs of sequential deceleration. The most recent quarterly revenue (Q4 2025) was $1.01 billion, representing a strong 44.4% year-over-year growth; however, this marks a deceleration from the 44.3% YoY growth in the prior quarter (Q3 2025: $993.7 million) and a peak of growth seen earlier in the year. The primary revenue driver is 'Health Care, Premium' at $425.8 million, significantly larger than 'Health Care Capitation' at $33.2 million. Profitability remains inconsistent and challenged, with the company swinging back to a net loss of -$11.0 million in Q4 2025 after posting net income of $3.7 million in Q3 2025 and $15.7 million in Q2 2025. The gross margin of 10.47% in Q4 2025 is notably lower than the 12.65% in Q3 2025, indicating margin compression. The operating margin was negative at -1.02% in Q4, down from a positive 0.77% in Q3. The balance sheet shows moderate liquidity but significant leverage. The current ratio is a healthy 1.74, indicating sufficient short-term liquidity. However, the debt-to-equity ratio is elevated at 1.89, signaling a leveraged capital structure. Trailing-twelve-month free cash flow is a positive $123.7 million, which provides internal funding capacity, but the return on equity is negative at -0.40%, reflecting inefficient use of shareholder capital given recent losses.
Quarterly Revenue
$1.0B
2025-12
Revenue YoY Growth
+0.44%
YoY Comparison
Gross Margin
+0.10%
Latest Quarter
Free Cash Flow
$123672000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALHC Overvalued?
Given the company's inconsistent profitability, with a trailing net income marginally negative at approximately -$0.0002, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 0.99, while the forward-looking valuation can be inferred from the Enterprise Value-to-Sales (EV/Sales) of 1.04. The minimal gap between these sales-based multiples suggests the market is not pricing in a significant acceleration in growth or margin expansion in the near term. Compared to industry averages, data is not available in the provided dataset for a direct sector PS or EV/Sales comparison, preventing a quantified premium/discount assessment. Historically, the stock's own PS ratio has fluctuated widely. The current PS of 0.99 is near the lower end of its observable historical range from the provided data, which has seen peaks above 13 in 2021 and was as low as 1.48 in early 2024. Trading near the bottom of its multi-year PS band suggests the market may be pricing in a degree of fundamental skepticism or that the stock offers a relative value opportunity if the company can stabilize its growth and path to profitability.
PE
-5401.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -99x~233x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
81.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced. ALHC operates with significant leverage, evidenced by a debt-to-equity ratio of 1.89, which amplifies risks amidst its inconsistent profitability. The company's gross margin compression from 12.65% in Q3 to 10.47% in Q4 2025 indicates operational inefficiency or rising medical costs that could erode the value of its revenue growth. Furthermore, revenue concentration in Medicare Advantage plans makes the company highly sensitive to changes in CMS reimbursement rates, despite the recent positive news, and its swing to a -$11.0M net loss in the latest quarter underscores earnings volatility.
Market & Competitive Risks are elevated. The stock trades with 20% more volatility than the market (beta 1.201), making it susceptible to sharp swings on sector news or growth stock rotations. While the current PS ratio of 0.99 appears low historically, the absence of profitability means the stock remains vulnerable to valuation compression if growth decelerates. Competitively, the Medicare Advantage space is dominated by large, profitable incumbents like UnitedHealth and Humana, which can leverage scale to compete on cost and benefits, potentially pressuring ALHC's margins and member acquisition costs further.
Worst-Case Scenario involves a combination of continued margin deterioration and a growth slowdown. If medical costs outpace premium increases and revenue growth decelerates from 44% toward industry averages, the company could report sustained and deepening losses. This could trigger a liquidity crisis given its high debt load, leading to equity dilution or restructuring. In this adverse scenario, the stock could realistically retest its 52-week low of $11.625, representing a potential downside of approximately -43% from the current price of $20.50. The historical max drawdown of -41.15% provides a precedent for such severe declines.
FAQ
The key risks are, in order of severity: 1) Profitability Risk: The inability to achieve consistent GAAP profits, as evidenced by the Q4 2025 net loss of -$11.0M and negative ROE. 2) Financial Risk: High leverage with a debt-to-equity ratio of 1.89, increasing bankruptcy risk if losses persist. 3) Operational Risk: Significant gross margin compression, falling from 12.65% to 10.47% in one quarter, threatening the business model. 4) Market Risk: High stock volatility (beta 1.201) and severe underperformance vs. the S&P 500 over one year (+3.64% vs. +29.52%).
The 12-month forecast for ALHC is highly bifurcated, with three distinct scenarios. The Base Case (50% probability) sees the stock range-bound between $19 and $23 as growth continues but profitability remains elusive. The Bull Case (25% probability) could drive the stock to $26-$30 on sustained profitability and margin expansion. The Bear Case (25% probability) could see a collapse to $11.625-$16 if losses widen and leverage concerns mount. The Base Case is most likely, predicated on the assumption that the company will struggle to consistently translate its strong revenue growth into bottom-line profits over the next year.
ALHC's valuation is contradictory. On a sales basis, it appears deeply undervalued, trading at a PS ratio of 0.99, which is near the bottom of its own historical range that has seen multiples above 13. However, on an earnings basis, it is overvalued or even un-investable, with a trailing P/E of -5401 and a forward P/E of 29.1 despite not being reliably profitable. The market is paying a fair price for its current sales but is implicitly assigning a high multiple to hoped-for future earnings. Compared to profitable healthcare peers, direct comparison is difficult, but the valuation implies the market expects significant future margin expansion.
ALHC is a high-risk, high-potential-reward stock that is not a good buy for most investors. For aggressive investors comfortable with volatility, it could be a speculative position. The 44% revenue growth and PS ratio of 0.99 (near historical lows) are compelling, but these are offset by the recent net loss of -$11M, margin compression, and high debt (D/E of 1.89). It is only a good buy for those who believe the company will imminently return to and sustain profitability, and who have a high risk tolerance for a potential -43% drawdown to its 52-week low.
ALHC is unsuitable for short-term trading due to its high volatility (beta 1.2) and lack of near-term catalysts beyond earnings, which are unpredictable. It is only suitable for a long-term (3-5 year) investment horizon, and only for investors who believe in the multi-year turnaround story and can withstand significant interim drawdowns. The company pays no dividend and its value is entirely tied to future earnings potential, which requires time to materialize. A minimum holding period of 2-3 years is suggested to see if the profitability thesis plays out, but investors must be prepared for the possibility of permanent capital impairment.